Cargando…
A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein
The convergence of human molecular genetics and Lewy pathology of Parkinson’s disease (PD) have led to a robust, clinical-stage pipeline of alpha-synuclein (α-syn)-targeted therapies that have the potential to slow or stop the progression of PD and other synucleinopathies. To facilitate the developm...
Autores principales: | Merchant, Kalpana M., Cedarbaum, Jesse M., Brundin, Patrik, Dave, Kuldip D., Eberling, Jamie, Espay, Alberto J., Hutten, Samantha J., Javidnia, Monica, Luthman, Johan, Maetzler, Walter, Menalled, Liliana, Reimer, Alyssa N., Stoessl, A. Jon, Weiner, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398545/ https://www.ncbi.nlm.nih.gov/pubmed/30400107 http://dx.doi.org/10.3233/JPD-181471 |
Ejemplares similares
-
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
por: Sardi, S. Pablo, et al.
Publicado: (2018) -
Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015) -
α‐Synuclein: The Long Distance Runner
por: George, Sonia, et al.
Publicado: (2013) -
A roadmap to ALS prevention: strategies and priorities
por: Benatar, Michael, et al.
Publicado: (2023) -
Editorial: Targeting α-Synuclein in Parkinson's Disease and Multiple System Atrophy
por: Fellner, Lisa, et al.
Publicado: (2022)